NCT06614855View on ClinicalTrials.gov

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
GlioblastomaGlioblastoma (GBM)AstrocytomaAstrocytoma, Grade IIIAstrocytoma, Grade IVGliosarcoma, AdultGliosarcoma of Brain
Interventions
DRUG

C134

Initial Treatment . C134 Dose #1

DRUG

C134

2nd Treatment. C134 Dose #2

Trial Locations (1)

35294

The University of Alabama at Birmingham Hospital, Birmingham

All Listed Sponsors
lead

James Markert, MD

OTHER

NCT06614855 - A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter